By 2017, the world RNA Interference market will be worth $4 billion, according to a new report available from companiesandmarkets.com. Growth is being driven by increased adoption of RNAi technology within the functional genomics research industry, where it is used for drug development, discovery and validation of therapeutic targets. There is also increased interest in RNA Interference for the purposes of agricultural and plant research.
RNA Interference (RNAi): A Global Strategic Business Report
The US and Europe represent the largest markets for RNAi, with Europe expected to grow rapidly, at a CAGR of 13.6% to 2017. The largest end use segment is drug discovery and target validation, followed by RNAi reagents which will increase share over the reporting period, growing at 15% CAGR, moving ahead of RNAi drug discovery.
The longer term RNA interference market is to be driven by the R&D of RNAi therapeutic drugs for various diseases; the first of which will emerge during 2013. Drug delivery represents a strong barrier to growth in this particular segment, as does stability and efficacy. The development of RNA interference therapeutics is still in its infancy, however many blockbuster drugs are expected to lose their patents in the next few years and it is likely that pharmaceutical companies will invest in RNAi therapies, to maximise chances of launching novel new drugs.
The RNAi research report includes profiles of 136 key industry participants, including Quark Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, Polyplus-transfection SA, Dicerna Pharmaceuticals Inc, Benitec Limited, Devgen NV, OPKO Health Inc, Bioneer Corp, Genesis Research & Development Corporation Limited, Calando Pharmaceuticals Inc, Dharmacon Inc and Cenix BioScience GmbH
RNA enzyme found key to heart cell energy shift after birth